SPIA
LTRN icon

Steward Partners Investment Advisory’s Lantern Pharma LTRN Stock Holding History

Steward Partners Investment Advisory’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-300
Closed -$1.81K – 3377
2022
Q4 		$1.81K Sell
300
-150
-33% -$751 ﹤0.01% 3032
2022
Q3 		$2K Hold
450
– – ﹤0.01% 3033
2022
Q2 		$3K Buy
450
+150
+50% +$895 ﹤0.01% 2921
2022
Q1 		$2K Hold
300
– – ﹤0.01% 3093
2021
Q4 		$2K Hold
300
– – ﹤0.01% 3024
2021
Q3 		$3K Buy
300
+50
+20% +$647 ﹤0.01% 2930
2021
Q2 		$4K Buy
+250
New +$3.86K ﹤0.01% 6695

Other funds holding LTRN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
HKAM
Horizon Kinetics Asset Management New York $9.23B AUM 27.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Steward Partners Investment Advisory's LTRN Position: Q1 2023 in Review

Steward Partners Investment Advisory sold out of Lantern Pharma (LTRN) in Q1 2023, closing a stake of 300 shares — an estimated $1.81K sold.

Steward Partners Investment Advisory first reported a position in LTRN in Q2 2021 and held it in 7 quarters. The position peaked at $4K in Q2 2021. 21 funds tracked by Wall St. Rank hold LTRN as of Q1 2023.

  • Steward Partners Investment Advisory reported no remaining Lantern Pharma position as of Q1 2023 after selling out during the quarter.
  • Steward Partners Investment Advisory sold 300 Lantern Pharma shares in Q1 2023, an estimated $1.81K.
  • Steward Partners Investment Advisory first reported a position in Lantern Pharma in Q2 2021 and held it in 7 quarters.
  • Steward Partners Investment Advisory's Lantern Pharma position peaked at $4K in Q2 2021.
  • 21 funds tracked by Wall St. Rank held Lantern Pharma as of Q1 2023.

Based on Steward Partners Investment Advisory's 13F filing for Q1 2023, filed 15 May 2023.